TA
Protara Therapeutics, Inc.
TARA · NASDAQ
$3.68 +3.81% (+$0.14)
1M -9.30%
Market Cap $206.8M
P/E Ratio -
Div. Yield -
ROE 41.72%
Bulios Fair Price
$2.53
31.3% downside
Current Price
$3.68
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TARA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 1.28x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 24.38%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 46.81%
ROE 41.72%
ROA 39.76%
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 10.97x
Int. coverage N/A
Stability
56 /100
Moderate Beta 1.49x
EPS volatility 0.52%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TARA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jesse Shefferman
Employees
46
Headquarters
New York City
Upcoming events
09 NOV
Earnings
Upcoming earnings report